Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 131

1.

Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile.

Skaug B, Khanna D, Swindell WR, Hinchcliff ME, Frech TM, Steen VD, Hant FN, Gordon JK, Shah AA, Zhu L, Zheng WJ, Browning JL, Barron AMS, Wu M, Visvanathan S, Baum P, Franks JM, Whitfield ML, Shanmugam VK, Domsic RT, Castelino FV, Bernstein EJ, Wareing N, Lyons MA, Ying J, Charles J, Mayes MD, Assassi S.

Ann Rheum Dis. 2019 Nov 25. pii: annrheumdis-2019-215894. doi: 10.1136/annrheumdis-2019-215894. [Epub ahead of print]

PMID:
31767698
2.

Perivascular Adventitial Fibroblast Specialization Accompanies T Cell Retention in the Inflamed Human Dermis.

Barron AMS, Mantero JC, Ho JD, Nazari B, Horback KL, Bhawan J, Lafyatis R, Lam C, Browning JL.

J Immunol. 2019 Jan 1;202(1):56-68. doi: 10.4049/jimmunol.1801209. Epub 2018 Dec 3.

3.

Extensive CD34-to-CD90 Fibroblast Transition Defines Regions of Cutaneous Reparative, Hypertrophic, and Keloidal Scarring.

Ho JD, Chung HJ, Ms Barron A, Ho DA, Sahni D, Browning JL, Bhawan J.

Am J Dermatopathol. 2019 Jan;41(1):16-28. doi: 10.1097/DAD.0000000000001254.

PMID:
30320623
4.

Clinical Efficacy and Safety of Baminercept, a Lymphotoxin β Receptor Fusion Protein, in Primary Sjögren's Syndrome: Results From a Phase II Randomized, Double-Blind, Placebo-Controlled Trial.

St Clair EW, Baer AN, Wei C, Noaiseh G, Parke A, Coca A, Utset TO, Genovese MC, Wallace DJ, McNamara J, Boyle K, Keyes-Elstein L, Browning JL, Franchimont N, Smith K, Guthridge JM, Sanz I, James JA; Autoimmunity Centers of Excellence.

Arthritis Rheumatol. 2018 Sep;70(9):1470-1480. doi: 10.1002/art.40513. Epub 2018 Jul 18.

5.

Dimethyl Fumarate ameliorates pulmonary arterial hypertension and lung fibrosis by targeting multiple pathways.

Grzegorzewska AP, Seta F, Han R, Czajka CA, Makino K, Stawski L, Isenberg JS, Browning JL, Trojanowska M.

Sci Rep. 2017 Feb 2;7:41605. doi: 10.1038/srep41605.

6.

Dendritic cells maintain dermal adipose-derived stromal cells in skin fibrosis.

Chia JJ, Zhu T, Chyou S, Dasoveanu DC, Carballo C, Tian S, Magro CM, Rodeo S, Spiera RF, Ruddle NH, McGraw TE, Browning JL, Lafyatis R, Gordon JK, Lu TT.

J Clin Invest. 2016 Nov 1;126(11):4331-4345. doi: 10.1172/JCI85740. Epub 2016 Oct 10.

7.

Pristane-Accelerated Autoimmune Disease in (SWR X NZB) F1 Mice Leads to Prominent Tubulointerstitial Inflammation and Human Lupus Nephritis-Like Fibrosis.

Gardet A, Chou WC, Reynolds TL, Velez DB, Fu K, Czerkowicz JM, Bajko J, Ranger AM, Allaire N, Kerns HM, Ryan S, Legault HM, Dunstan RW, Lafyatis R, Lukashev M, Viney JL, Browning JL, Rabah D.

PLoS One. 2016 Oct 19;11(10):e0164423. doi: 10.1371/journal.pone.0164423. eCollection 2016.

8.

Altered Dermal Fibroblasts in Systemic Sclerosis Display Podoplanin and CD90.

Nazari B, Rice LM, Stifano G, Barron AM, Wang YM, Korndorf T, Lee J, Bhawan J, Lafyatis R, Browning JL.

Am J Pathol. 2016 Oct;186(10):2650-64. doi: 10.1016/j.ajpath.2016.06.020. Epub 2016 Aug 23.

9.

Lymphotoxin β receptor signalling executes Helicobacter pylori-driven gastric inflammation in a T4SS-dependent manner.

Mejías-Luque R, Zöller J, Anderl F, Loew-Gil E, Vieth M, Adler T, Engler DB, Urban S, Browning JL, Müller A, Gerhard M, Heikenwalder M.

Gut. 2017 Aug;66(8):1369-1381. doi: 10.1136/gutjnl-2015-310783. Epub 2016 Apr 13.

PMID:
27196595
10.

Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma.

Finkin S, Yuan D, Stein I, Taniguchi K, Weber A, Unger K, Browning JL, Goossens N, Nakagawa S, Gunasekaran G, Schwartz ME, Kobayashi M, Kumada H, Berger M, Pappo O, Rajewsky K, Hoshida Y, Karin M, Heikenwalder M, Ben-Neriah Y, Pikarsky E.

Nat Immunol. 2015 Dec;16(12):1235-44. doi: 10.1038/ni.3290. Epub 2015 Oct 26.

11.

The lymphotoxin β receptor is a potential therapeutic target in renal inflammation.

Seleznik G, Seeger H, Bauer J, Fu K, Czerkowicz J, Papandile A, Poreci U, Rabah D, Ranger A, Cohen CD, Lindenmeyer M, Chen J, Edenhofer I, Anders HJ, Lech M, Wüthrich RP, Ruddle NH, Moeller MJ, Kozakowski N, Regele H, Browning JL, Heikenwalder M, Segerer S.

Kidney Int. 2016 Jan;89(1):113-26. doi: 10.1038/ki.2015.280. Epub 2016 Jan 4.

PMID:
26398497
12.

A longitudinal biomarker for the extent of skin disease in patients with diffuse cutaneous systemic sclerosis.

Rice LM, Ziemek J, Stratton EA, McLaughlin SR, Padilla CM, Mathes AL, Christmann RB, Stifano G, Browning JL, Whitfield ML, Spiera RF, Gordon JK, Simms RW, Zhang Y, Lafyatis R.

Arthritis Rheumatol. 2015 Nov;67(11):3004-15. doi: 10.1002/art.39287.

13.

Lymphotoxin-LIGHT pathway regulates the interferon signature in rheumatoid arthritis.

Bienkowska J, Allaire N, Thai A, Goyal J, Plavina T, Nirula A, Weaver M, Newman C, Petri M, Beckman E, Browning JL.

PLoS One. 2014 Nov 18;9(11):e112545. doi: 10.1371/journal.pone.0112545. eCollection 2014.

14.

The Lymphotoxin Network: orchestrating a type I interferon response to optimize adaptive immunity.

Gommerman JL, Browning JL, Ware CF.

Cytokine Growth Factor Rev. 2014 Apr;25(2):139-45. doi: 10.1016/j.cytogfr.2014.02.002. Epub 2014 Mar 12. Review.

15.

Role of the Lymphotoxin/LIGHT System in the Development and Maintenance of Reticular Networks and Vasculature in Lymphoid Tissues.

Lu TT, Browning JL.

Front Immunol. 2014 Feb 11;5:47. doi: 10.3389/fimmu.2014.00047. eCollection 2014. Review.

16.

Pillars article: A lymphotoxin-B-specific receptor. Science. 1994. 264: 707-710.

Crowe PD, Vanarsdale TL, Walter BN, Ware CF, Hession C, Ehrenfels B, Browning JL, Din WS, Goodwin RG, Smith CA.

J Immunol. 2014 Mar 1;192(5):2015-8. No abstract available.

17.

Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA.

Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, Sprinzl MF, Koppensteiner H, Makowska Z, Volz T, Remouchamps C, Chou WM, Thasler WE, Hüser N, Durantel D, Liang TJ, Münk C, Heim MH, Browning JL, Dejardin E, Dandri M, Schindler M, Heikenwalder M, Protzer U.

Science. 2014 Mar 14;343(6176):1221-8. doi: 10.1126/science.1243462. Epub 2014 Feb 20.

18.

Feasibility of the use of combinatorial chemokine arrays to study blood and CSF in multiple sclerosis.

Edwards KR, Goyal J, Plavina T, Czerkowicz J, Goelz S, Ranger A, Cadavid D, Browning JL.

PLoS One. 2013 Nov 20;8(11):e81007. doi: 10.1371/journal.pone.0081007. eCollection 2013.

19.

Lymphotoxin β receptor mediates caspase-dependent tumor cell apoptosis in vitro and tumor suppression in vivo despite induction of NF-κB activation.

Hu X, Zimmerman MA, Bardhan K, Yang D, Waller JL, Liles GB, Lee JR, Pollock R, Lev D, Ware CF, Garber E, Bailly V, Browning JL, Liu K.

Carcinogenesis. 2013 May;34(5):1105-14. doi: 10.1093/carcin/bgt014. Epub 2013 Jan 24. No abstract available.

20.

Lymphotoxin β receptor signaling promotes development of autoimmune pancreatitis.

Seleznik GM, Reding T, Romrig F, Saito Y, Mildner A, Segerer S, Sun LK, Regenass S, Lech M, Anders HJ, McHugh D, Kumagi T, Hiasa Y, Lackner C, Haybaeck J, Angst E, Perren A, Balmer ML, Slack E, MacPherson A, Manz MG, Weber A, Browning JL, Arkan MC, Rülicke T, Aguzzi A, Prinz M, Graf R, Heikenwalder M.

Gastroenterology. 2012 Nov;143(5):1361-1374. doi: 10.1053/j.gastro.2012.07.112. Epub 2012 Aug 2.

21.

Follicular dendritic cells emerge from ubiquitous perivascular precursors.

Krautler NJ, Kana V, Kranich J, Tian Y, Perera D, Lemm D, Schwarz P, Armulik A, Browning JL, Tallquist M, Buch T, Oliveira-Martins JB, Zhu C, Hermann M, Wagner U, Brink R, Heikenwalder M, Aguzzi A.

Cell. 2012 Jul 6;150(1):194-206. doi: 10.1016/j.cell.2012.05.032.

22.

Regulation of T(H)2 development by CXCR5+ dendritic cells and lymphotoxin-expressing B cells.

León B, Ballesteros-Tato A, Browning JL, Dunn R, Randall TD, Lund FE.

Nat Immunol. 2012 May 27;13(7):681-90. doi: 10.1038/ni.2309.

23.

Lymphotoxin and the amazing technicolor circus of intestinal homeostasis.

Browning JL.

Mucosal Immunol. 2012 May;5(3):228-31. doi: 10.1038/mi.2012.3. Epub 2012 Feb 8.

PMID:
22318496
24.

Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans.

Srinivasan M, Flynn R, Price A, Ranger A, Browning JL, Taylor PA, Ritz J, Antin JH, Murphy WJ, Luznik L, Shlomchik MJ, Panoskaltsis-Mortari A, Blazar BR.

Blood. 2012 Feb 9;119(6):1570-80. doi: 10.1182/blood-2011-07-364414. Epub 2011 Nov 9.

25.

Lymphotoxin-beta receptor blockade reduces CXCL13 in lacrimal glands and improves corneal integrity in the NOD model of Sjögren's syndrome.

Fava RA, Kennedy SM, Wood SG, Bolstad AI, Bienkowska J, Papandile A, Kelly JA, Mavragani CP, Gatumu M, Skarstein K, Browning JL.

Arthritis Res Ther. 2011;13(6):R182. doi: 10.1186/ar3507. Epub 2011 Nov 1.

26.

Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy.

McCarthy DD, Kujawa J, Wilson C, Papandile A, Poreci U, Porfilio EA, Ward L, Lawson MA, Macpherson AJ, McCoy KD, Pei Y, Novak L, Lee JY, Julian BA, Novak J, Ranger A, Gommerman JL, Browning JL.

J Clin Invest. 2011 Oct;121(10):3991-4002. doi: 10.1172/JCI45563. Epub 2011 Sep 1. Erratum in: J Clin Invest. 2012 Feb 1;122(2):778.

27.

LTBR-pathway in Sjogren's syndrome: CXCL13 levels and B-cell-enriched ectopic lymphoid aggregates in NOD mouse lacrimal glands are dependent on LTBR.

Fava RA, Browning JL, Gatumu M, Skarstein K, Bolstad AI.

Adv Exp Med Biol. 2011;691:383-90. doi: 10.1007/978-1-4419-6612-4_39. No abstract available.

PMID:
21153342
28.

Workshop summary: control of lymphocyte function and repertoire by the TNF superfamily.

Ware CF, Browning JL.

Adv Exp Med Biol. 2011;691:351-2. doi: 10.1007/978-1-4419-6612-4_35. No abstract available.

PMID:
21153338
29.

Increased intracranial pressure is associated with elevated cerebrospinal fluid ADH levels in closed-head injury.

Widmayer MA, Browning JL, Gopinath SP, Robertson CS, Baskin DS.

Neurol Res. 2010 Dec;32(10):1021-6. doi: 10.1179/016164110X12714125204155. Epub 2010 Aug 31.

PMID:
20810023
30.

TRAF3 controls activation of the canonical and alternative NFkappaB by the lymphotoxin beta receptor.

Bista P, Zeng W, Ryan S, Bailly V, Browning JL, Lukashev ME.

J Biol Chem. 2010 Apr 23;285(17):12971-8. doi: 10.1074/jbc.M109.076091. Epub 2010 Feb 25.

31.

A lymphotoxin-driven pathway to hepatocellular carcinoma.

Haybaeck J, Zeller N, Wolf MJ, Weber A, Wagner U, Kurrer MO, Bremer J, Iezzi G, Graf R, Clavien PA, Thimme R, Blum H, Nedospasov SA, Zatloukal K, Ramzan M, Ciesek S, Pietschmann T, Marche PN, Karin M, Kopf M, Browning JL, Aguzzi A, Heikenwalder M.

Cancer Cell. 2009 Oct 6;16(4):295-308. doi: 10.1016/j.ccr.2009.08.021. Erratum in: Cancer Cell. 2009 Nov 6;16(5):447.

32.

Blockade of lymphotoxin-beta receptor signaling reduces aspects of Sjögren's syndrome in salivary glands of non-obese diabetic mice.

Gatumu MK, Skarstein K, Papandile A, Browning JL, Fava RA, Bolstad AI.

Arthritis Res Ther. 2009;11(1):R24. doi: 10.1186/ar2617. Epub 2009 Feb 18.

33.

Using simulation to orient code blue teams to a new hospital facility.

Villamaria FJ, Pliego JF, Wehbe-Janek H, Coker N, Rajab MH, Sibbitt S, Ogden PE, Musick K, Browning JL, Hays-Grudo J.

Simul Healthc. 2008 Winter;3(4):209-16. doi: 10.1097/SIH.0b013e31818187f3.

PMID:
19088665
34.

OB/GYN boot cAMP using high-fidelity human simulators: enhancing residents' perceived competency, confidence in taking a leadership role, and stress hardiness.

Pliego JF, Wehbe-Janek H, Rajab MH, Browning JL, Fothergill RE.

Simul Healthc. 2008 Summer;3(2):82-9. doi: 10.1097/SIH.0b013e3181658188.

PMID:
19088646
35.

Inhibition of the lymphotoxin pathway as a therapy for autoimmune disease.

Browning JL.

Immunol Rev. 2008 Jun;223:202-20. doi: 10.1111/j.1600-065X.2008.00633.x. Review.

PMID:
18613838
36.

Recombinant prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicity.

Singh R, Browning JL, Abi-Habib R, Wong K, Williams SA, Merchant R, Denmeade SR, Buckley TJ, Frankel AE.

Anticancer Drugs. 2007 Aug;18(7):809-16.

PMID:
17581303
37.

Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy.

Lukashev M, LePage D, Wilson C, Bailly V, Garber E, Lukashin A, Ngam-ek A, Zeng W, Allaire N, Perrin S, Xu X, Szeliga K, Wortham K, Kelly R, Bottiglio C, Ding J, Griffith L, Heaney G, Silverio E, Yang W, Jarpe M, Fawell S, Reff M, Carmillo A, Miatkowski K, Amatucci J, Crowell T, Prentice H, Meier W, Violette SM, Mackay F, Yang D, Hoffman R, Browning JL.

Cancer Res. 2006 Oct 1;66(19):9617-24.

38.

B cells move to centre stage: novel opportunities for autoimmune disease treatment.

Browning JL.

Nat Rev Drug Discov. 2006 Jul;5(7):564-76. Review.

PMID:
16816838
39.

Lymphotoxin-beta receptor signaling is required for the homeostatic control of HEV differentiation and function.

Browning JL, Allaire N, Ngam-Ek A, Notidis E, Hunt J, Perrin S, Fava RA.

Immunity. 2005 Nov;23(5):539-50.

40.

Clozapine and the mitogen-activated protein kinase signal transduction pathway: implications for antipsychotic actions.

Browning JL, Patel T, Brandt PC, Young KA, Holcomb LA, Hicks PB.

Biol Psychiatry. 2005 Mar 15;57(6):617-23.

PMID:
15780848
41.

TAJ/TROY, an orphan TNF receptor family member, binds Nogo-66 receptor 1 and regulates axonal regeneration.

Shao Z, Browning JL, Lee X, Scott ML, Shulga-Morskaya S, Allaire N, Thill G, Levesque M, Sah D, McCoy JM, Murray B, Jung V, Pepinsky RB, Mi S.

Neuron. 2005 Feb 3;45(3):353-9.

42.

Lymphotoxin/light, lymphoid microenvironments and autoimmune disease.

Gommerman JL, Browning JL.

Nat Rev Immunol. 2003 Aug;3(8):642-55. Review.

PMID:
12974479
43.

A role for surface lymphotoxin in experimental autoimmune encephalomyelitis independent of LIGHT.

Gommerman JL, Giza K, Perper S, Sizing I, Ngam-Ek A, Nickerson-Nutter C, Browning JL.

J Clin Invest. 2003 Sep;112(5):755-67.

44.

A role for the lymphotoxin/LIGHT axis in the pathogenesis of murine collagen-induced arthritis.

Fava RA, Notidis E, Hunt J, Szanya V, Ratcliffe N, Ngam-Ek A, De Fougerolles AR, Sprague A, Browning JL.

J Immunol. 2003 Jul 1;171(1):115-26.

46.

Manipulation of lymphoid microenvironments in nonhuman primates by an inhibitor of the lymphotoxin pathway.

Gommerman JL, Mackay F, Donskoy E, Meier W, Martin P, Browning JL.

J Clin Invest. 2002 Nov;110(9):1359-69.

47.

BAFF: a fundamental survival factor for B cells.

Mackay F, Browning JL.

Nat Rev Immunol. 2002 Jul;2(7):465-75. Review.

PMID:
12094221
48.
49.

BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF.

Thompson JS, Bixler SA, Qian F, Vora K, Scott ML, Cachero TG, Hession C, Schneider P, Sizing ID, Mullen C, Strauch K, Zafari M, Benjamin CD, Tschopp J, Browning JL, Ambrose C.

Science. 2001 Sep 14;293(5537):2108-11. Epub 2001 Aug 16.

50.

Elimination of colonic patches with lymphotoxin beta receptor-Ig prevents Th2 cell-type colitis.

Dohi T, Rennert PD, Fujihashi K, Kiyono H, Shirai Y, Kawamura YI, Browning JL, McGhee JR.

J Immunol. 2001 Sep 1;167(5):2781-90.

Supplemental Content

Loading ...
Support Center